Australia's CSL falls to over 8-yr low as Pentagon ends flu vaccine mandate
** Shares of CSL CSL.AX fall as much as 1% to A$127.75, their lowest level since August 31, 2017 ** The biotech giant is down over 6% for the week, logging its worst week since mid-February ** Slide after Pentagon's decision to scrap its flu vaccine mandate, marking a reversal from a long-standing requirement and raising concerns about demand from a key institutional buyer ** Stock down 25.7% YTD (Reporting by Anjali Singh in Bengaluru) ((anjali.singh2@thomsonreuters.com;))
Recent news on Csl
See all newsEU Commission opens antitrust probe into Sanofi's flu vaccine campaign (updated)
EU Commission opens antitrust probe into Sanofi's flu vaccine campaign
Analysis: US prices for new drugs fell in 2025 as fewer costly gene therapies were launched
US military requires flu vaccine for some after outbreak in Texas training center
Corrected: BUZZ-Australian healthcare stocks hit a six-week high, acting as a primary hedge on ASX